Drug Profile
TERT-induced adoptive T cell therapy - Eutilex
Alternative Names: hTERT; Telomerase reverse transcriptase-induced natural T cell therapy - Eutilex; TERT 4-1BB CTL - Eutilex; TERT-induced natural T cell therapy - Eutilex; TERTiNT - EutilexLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Eutilex
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action CD8 positive T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (Parenteral, Infusion)
- 30 Sep 2020 TERT-induced adoptive T cell therapy is still in phase I trials for Solid tumour in South Korea (Eutilex pipeline, September 2020)
- 06 Nov 2017 Phase-I clinical trials in Solid tumour in South Korea (Parenteral) before November 2017 (Eutilex pipeline, November 2017)